Global Pneumococcal Vaccine Market - Strategic Insights and Forecasts (2026-2031)

The global pneumococcal vaccine market is forecast to reach USD 14.51 billion in 2031, growing from USD 10.73 billion in 2026. This represents a robust Compound Annual Growth Rate (CAGR) of 6.2% over the strategic forecast period, indicating a strong upward trend in demand.

Major driving factors include the implementation of regular vaccination programs under national policies and rising global awareness against pneumonia. Additionally, directives launched by organizations such as WHO and UNICEF, alongside increasing government support for immunization, are significantly contributing to the market's growth.

The South Asian region shows the highest incidence rate of childhood pneumonia, with 2,500 cases per 100,000 children. The West and Central African region also reports a significant incidence rate of 1,620 cases per 100,000 children, highlighting these areas as key drivers for pneumococcal vaccine demand.

Childhood pneumonia presents a substantial burden, being the highest cause of fatalities among infectious diseases in children under five, accounting for over 800 thousand deaths annually. This alarming statistic, coupled with a global incidence of 1,400 cases per 100,000 children, creates an urgent need and robust demand for pneumococcal vaccines to combat child mortality.

International organizations like WHO, UNICEF, and UNDP, in conjunction with national governments, are crucial in reducing pneumonia infection rates through various initiatives. They implement comprehensive vaccine programs, such as the nationwide expansion of pneumococcal conjugate vaccine (PCV) under universal immunization programs, which expand market reach and introduce novel products.

Yes, the report references the nationwide expansion of pneumococcal conjugate vaccine (PCV) launched by the Ministry of Health under the 'Universal Immunization Program' as a key initiative. These plans aim to spread awareness and boost the immune system of children aged under 5 years through appropriate vaccines, thereby expanding product portfolios and market reach.